Goserelin

Introduction Overview

Generic Name

goserelin

Brand Name

Zoladex

Dosage Form

implant (subcutaneous depot injection)

Drug Class

Gonadotropin releasing hormones; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Goserelin is administered subcutaneously as a depot implant, predominantly into the anterior abdominal wall. Upon implantation, the drug is released slowly and steadily through diffusion from the biodegradable polymer matrix of the implant. Peak plasma concentrations are attained within a few hours following implantation, ensuring timely onset of pharmacodynamic effects. The absorption profile is sustained, with continuous release maintaining hormone suppression over the dosing interval, which can range from 28 days with the 3.6 mg implant to 12 weeks with the 10.8 mg implant. Variability in absorption may occur based on subcutaneous tissue characteristics but is clinically insignificant due to dosage regimen design.

Distribution:
Following systemic absorption, goserelin extensively distributes throughout the body. It exhibits low plasma protein binding, allowing free drug to interact with pituitary gonadotropin receptors. Due to its peptide nature and molecular size, goserelin does not readily cross the blood-brain barrier but exerts its effects by acting on the hypothalamic-pituitary axis. The volume of distribution is relatively low, consistent with its mechanism that is confined largely to endocrine tissues. Local tissue concentrations near the pituitary contribute to its efficacy in downregulating gonadotropin release.

Metabolism:
Goserelin undergoes enzymatic hydrolysis by peptidases to inactive fragments, primarily in the liver and peripheral tissues. It is structurally analogous to native luteinizing hormone-releasing hormone (LHRH), but the synthetic modifications confer resistance to rapid degradation. Unlike small molecule drugs metabolized by cytochrome P450 enzymes, goserelin's peptide metabolism minimizes drug interactions at the metabolic level. The metabolites possess no significant pharmacological activity.

Elimination:
The inactive metabolites of goserelin are primarily eliminated via renal excretion. The parent peptide itself is cleared relatively rapidly from systemic circulation once absorption from the implant depot declines. The pharmacologic effect persists as long as sufficient plasma concentrations are maintained by depot release. The elimination half-life is not fixed but is functionally extended due to the continuous subcutaneous delivery. Renal impairment does not significantly alter goserelin elimination due to its metabolism-first clearance. Overall, goserelin’s pharmacokinetics are consistent with extended-release peptide hormone therapy, ensuring steady suppression of gonadotropin secretion.

Dosage Forms

Available Dosage Forms:
Zoladex is available as a ready-to-use subcutaneous implant designed for depot injection into the anterior abdominal wall. The implant is contained in a preloaded syringe and administered via a specialized needle. Two main dosage strengths are available:
- Implant 3.6 mg (28-day release)
- Implant 10.8 mg (12-week release)

Dosages for Adults and Adolescents:
- Prostate Cancer (Palliative Treatment):
* 3.6 mg implant administered subcutaneously once every 28 days.
* 10.8 mg implant administered once every 12 weeks.
* Combination regimens involving initial 3.6 mg implant followed by 10.8 mg implant 28 days later are used, especially in conjunction with radiotherapy and antiandrogen therapy for stage B2 to C prostate cancer.
- Breast Cancer (Palliative):
* 3.6 mg subcutaneous implant every 28 days for premenopausal and perimenopausal women.
- Endometriosis:
* 3.6 mg implant once every 28 days for up to 6 months duration.
- Abnormal Uterine Bleeding (Preoperative Endometrial Ablation):
* 1 or 2 doses of 3.6 mg implants spaced 4 weeks apart prior to surgery, with surgery scheduled within 2 to 4 weeks after the last dose.

Specific Patient Populations:
- In patients receiving chemotherapy, dosing schedules may be adjusted per oncologist recommendations.
- Premenopausal women require non-hormonal contraception during treatment and for at least 12 weeks after discontinuation due to the potential for ovulation despite hormonal suppression.
- The implant is designed to dissolve over time, typically not causing discomfort or requiring removal.
- Special monitoring may be warranted for patients with osteoporosis risk factors, diabetes, or cardiovascular diseases.
The ready-to-use implant syringe does not require refrigeration. Administration is performed in a clinical setting by trained healthcare professionals.

Mechanism Of Action

Goserelin, the active ingredient in Zoladex, is a synthetic analogue of gonadotropin-releasing hormone (GnRH or LHRH) with potent agonist activity. It binds with high affinity to GnRH receptors located on the anterior pituitary gonadotroph cells, initiating a cascade of intracellular events. Upon initial administration, goserelin stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a transient surge in gonadal steroid production such as testosterone in men and estrogen in women.

However, the continuous administration of goserelin via the depot implant leads to downregulation and desensitization of pituitary GnRH receptors. This receptor downregulation results in the suppression of LH and FSH secretion after an initial flare, profoundly reducing gonadal steroidogenesis. The induced hypogonadotropic hypogonadism mimics a reversible medical castration state in men and decreases estrogen production in women, which is therapeutically utilized in hormone-dependent conditions.

In prostate cancer, the decrease in testosterone reduces androgen stimulation of prostate tumor cells, impeding tumor growth and progression. Similarly, in breast cancer, reduction of circulating estrogens limits hormone-sensitive tumor proliferation. In endometriosis, diminished estrogen levels reduce ectopic endometrial tissue growth and associated pain.

The molecular mechanism involves alteration in GnRH receptor signaling pathways, including G-protein coupled receptor desensitization and internalization. This leads to reduced cyclic AMP production and calcium mobilization downstream, thereby attenuating gonadotropin release. Clinical studies have demonstrated that continuous LHRH agonists like goserelin effectively sustain pituitary desensitization and hormonal suppression with good tolerability.

Compared to GnRH antagonists, which block receptors directly, goserelin induces suppression through receptor overstimulation followed by downregulation. This results in an initial hormone flare that may necessitate concomitant antiandrogen therapy in prostate cancer to mitigate disease exacerbation. Overall, goserelin’s mechanism provides a controllable and reversible hormone suppression method with applications in multiple hormone-dependent diseases.

Pharmacological Actions

Acts as a potent agonist of gonadotropin-releasing hormone (GnRH) receptors in the anterior pituitary.
Initially stimulates LH and FSH secretion, causing a transient increase in gonadal steroids (testosterone, estrogen).
Continuously suppresses LH and FSH secretion by downregulating pituitary GnRH receptors, leading to decreased gonadal steroidogenesis.
Induces reversible hypogonadotropic hypogonadism mimicking chemical castration.
In prostate cancer, reduces androgen-dependent tumor growth through testosterone suppression.
In breast cancer, decreases estrogen levels to inhibit hormone-sensitive tumor proliferation.
Suppresses ectopic endometrial tissue proliferation and associated pain in endometriosis by lowering estrogen.
Mimics physiological downregulation of the hypothalamic-pituitary-gonadal axis upon continuous exposure.
Demonstrates dose-dependent duration of action based on implant strength and release kinetics.
Has no significant activity outside reproductive hormone axis due to selectivity for GnRH receptors.
Requires clinical management of initial hormone flare with antiandrogen therapy when used for prostate cancer.
Biodegradable implant formulation ensures sustained steady drug release with minimal peak-trough fluctuations.
Minimal drug metabolism-related drug interactions due to peptide nature and non-CYP metabolism.
Elicits predictable endocrine and clinical responses validated in multiple controlled studies.
Limited ability to cross blood-brain barrier, acting mainly on pituitary gonadotroph cells.

Therapeutic Or Clinical Uses

Palliative treatment of advanced prostate cancer, both as monotherapy and in combination with antiandrogens and radiotherapy.
Management of locoregionally confined prostate carcinoma (Stage B2 to C) in combination with flutamide and radiotherapy.
Palliative treatment of advanced breast cancer in premenopausal and perimenopausal women by estrogen suppression.
Management of endometriosis, including reduction of endometriotic lesions and amelioration of pain symptoms.
Preoperative hormonal preparation of the endometrium prior to surgical endometrial ablation for dysfunctional uterine bleeding.
Off-label use in hormone-sensitive gynecological disorders requiring medical castration or hormone suppression.
Adjunctive therapy with chemotherapy in hormone-responsive cancers as per oncologist discretion.
As part of combination treatment regimens for advanced hormone-dependent malignancies.
Temporary suppression of ovulation and menstruation in premenopausal women undergoing specified surgical procedures.
Reduction of hormone-driven symptoms such as vaginal dryness and breast tenderness related to gynecologic conditions.
Management of abnormal uterine bleeding related to hormonal imbalances and endometrial pathology.
Investigational or limited use in certain cases of hormone-dependent benign tumors or conditions responsive to downregulation of gonadotropins.
Has been used to prepare patients for surgical interventions through hormonal suppression.
Used in clinical settings when reversible suppression of gonadal steroids is necessary for disease management.

Side Or Adverse Effects

Hot flashes and sweating due to induced hypoestrogenism or hypoandrogenism.
Painful or difficult urination reflecting changes in urinary tract symptoms during treatment initiation.
Headache, which may be transient and associated with hormonal fluctuations.
Mood changes including depression, irritability, or changes in libido (increased or decreased interest in sex).
Sexual dysfunction such as decreased potency and fewer erections in males.
Swelling or edema in the hands or feet due to fluid retention.
Vaginal dryness, itching, or abnormal discharge resulting from estrogen deficiency in women.
Changes in breast size reflecting hormonal alterations.
Acne, mild skin rash, or localized itching associated with hormonal changes or injection site reactions.
Injection site reactions including pain, bruising, swelling, redness, oozing, or bleeding.
Alopecia or hair thinning, particularly seen in females; can be mild to severe.
Weight gain observed in a minority of patients during treatment.
Hyperglycemia with symptoms such as increased thirst and urination, dry mouth, and fruity breath odor.
Hypercalcemia presenting with nausea, vomiting, constipation, confusion, and weight loss.
Rare allergic reactions including hives, facial swelling, or anaphylaxis.
Potential worsening or flare of tumor symptoms initially, including increased spinal cord or urinary tract pressure.
Cardiovascular symptoms such as chest pain or signs of blood clots in some patients.
Neurologic symptoms including dizziness, numbness, or coordination problems that require immediate attention.

Precautions

Not recommended during pregnancy except in specific cases of advanced breast cancer where benefits outweigh risks.
Use effective non-hormonal contraception during treatment and for at least 12 weeks post-therapy due to risk of pregnancy despite menstrual suppression.
Do not breastfeed while receiving therapy due to potential harm to the infant.
Screen and monitor bone mineral density regularly due to increased risk of osteoporosis and bone loss.
Patients with history of cardiovascular disease, heart attack, stroke, or risk factors for coronary artery disease should be closely monitored.
Use caution in patients with diabetes due to potential alterations in blood glucose control.
Carefully evaluate patients with spinal conditions prior to therapy as tumor flares may exacerbate neurological symptoms.
Patients with abnormal uterine bleeding should be evaluated to exclude serious causes before initiating treatment.
Avoid use in patients allergic to goserelin or related GnRH analogues such as leuprolide, nafarelin, or ganirelix.
Monitor for signs of injection site infection or severe local reactions.
Assess patient's mental health status before and during treatment due to risk of mood changes and depression.
Advise patients to avoid smoking and excessive alcohol consumption to reduce bone loss and cardiovascular risk.
Regular monitoring of blood glucose and calcium levels is recommended during therapy.
Inform patients about potential initial worsening of symptoms and instruct to report serious neurological or urinary symptoms immediately.
Use with caution in patients with long QT syndrome or family history to prevent serious cardiac arrhythmias.

Warnings

Goserelin can cause harm to an unborn baby and is contraindicated during pregnancy unless used for advanced breast cancer under strict medical supervision.
Effective non-hormonal contraception is mandatory during treatment and for at least 12 weeks after discontinuation to prevent pregnancy.
Do not breastfeed while on Zoladex therapy due to potential risk to the infant.
Initial hormone surge (flare) may worsen symptoms of prostate cancer, potentially causing spinal cord compression or urinary obstruction; monitoring and concurrent antiandrogens may be necessary.
Risk of decreased bone mineral density leading to osteoporosis, particularly with long-term use.
Potential serious cardiovascular events including heart attack, stroke, and thromboembolic phenomena have been noted; patients with relevant risk factors should be carefully evaluated.
May cause serious allergic reactions including anaphylaxis; patients should be educated to recognize symptoms.
Use caution in patients with a history of abnormal bleeding or coagulation disorders.
May cause hyperglycemia and diabetes mellitus exacerbations; monitor blood glucose levels.
High calcium levels (hypercalcemia) can occur and require medical management.
Drug may interfere with certain laboratory tests; inform healthcare providers of therapy to avoid misinterpretation.
Patients should be observed for neurological symptoms such as numbness, weakness, or loss of bladder/bowel control indicating possible spinal cord compression.
Avoid concomitant use with drugs known to prolong the QT interval or cause cardiac arrhythmias unless necessary and under close supervision.
Not recommended for use in patients allergic to GnRH agonists such as leuprolide or nafarelin.
Missed doses may lead to loss of therapeutic hormone suppression and breakthrough bleeding or ovulation.

Contraindication

Known hypersensitivity or allergy to goserelin or any component of the implant formulation.
Allergy to other GnRH agonists such as leuprolide, nafarelin, histrelin, or ganirelix.
Pregnancy except in exceptional cases of advanced breast cancer where benefits outweigh risks.
Breastfeeding mothers due to risk of drug transmission and harm to infant.
Severe osteoporosis or metabolic bone disease without adequate management.
Patients with unexplained abnormal vaginal bleeding until diagnosis has been established.
History of long QT syndrome or clinically significant cardiac arrhythmias may preclude use.
Concurrent conditions where hormone suppression may be harmful or contraindicated as judged by the treating physician.
Use has not been established in pediatric patients; safety and efficacy unknown.
Known active infection at the potential implant site to avoid local complications.
Severe renal or hepatic impairment may require special consideration although not an absolute contraindication.
Patients unable to comply with regular monitoring and follow-up protocols.

Drug Interactions

Concurrent use with antiandrogens such as flutamide is common in prostate cancer therapy to mitigate tumor flare during initial treatment.
May interact with drugs that prolong QT interval, increasing risk of cardiac arrhythmias, including certain antibiotics, antipsychotics, and antiarrhythmics.
Interactions with blood thinners like warfarin may alter bleeding risk; close monitoring of INR is advised.
Potential interaction with medications used to treat infections, asthma, hypertension, depression, mental illness, cancer, malaria, or HIV which may increase cardiac risk when combined.
Concomitant use of seizure medications or corticosteroids may increase risk of bone mineral density loss and osteoporosis.
No significant cytochrome P450 mediated interactions due to peptide nature of goserelin.
Herbal supplements and over-the-counter products should be disclosed to physician to assess for potential additive endocrine effects.
May affect laboratory test results by altering hormone and biochemical parameters; healthcare providers should be informed of goserelin use.
Possible interaction with diabetes medications requiring dose adjustments due to changes in glucose metabolism.
NSAIDs and drugs influencing coagulation require caution due to potential additive bleeding risks.
Hormonal contraceptives are ineffective during treatment; recommend non-hormonal methods.
Monitoring required if combined with other hormone therapies or oncology agents.
No large-scale data on interactions with novel oncology drugs like PARP inhibitors or immune checkpoint inhibitors; caution advised.
Potential pharmacodynamic interactions with androgen receptor antagonists necessitating clinical monitoring.
Patients receiving immunosuppressants or chemotherapy should follow tailored dosing schedules.

Preparations Of The Drug

Zoladex implant presented in a sterile, prefilled disposable syringe with a 16-gauge needle.
Two primary implant strengths available: 3.6 mg (28-day depot) and 10.8 mg (12-week depot).
The implant is a biodegradable polymer matrix containing goserelin acetate designed for sustained subcutaneous release.
Storage does not require refrigeration; stable at room temperature prior to administration.
Single-use syringe system with safety features including needle cover and plunger lock mechanism.
Ready-to-administer to minimize preparation errors and maintain sterility during implantation.
Accompanying instructions for administration include cleansing the injection site and aseptic techniques.
The implant dissolves gradually after insertion, negating the need for removal.
Packaging designed to protect the implant during transport and prevent mechanical damage.
Not compatible with mixing or dilution; administered as provided by manufacturer.
Available with safety features to reduce risk of needlestick injury to healthcare providers.
Disposal instructions comply with biomedical hazardous waste protocols.
Manufactured under strict aseptic and quality-controlled conditions.
Includes patient information leaflet outlining usage, precautions, and side effects.
Approved formulations allow for flexible dosing regimens tailored to clinical indications.